TG Therapeutics (TGTX) Q1 2026: BrionV Rx Base Climbs Past 25,000, Doubling Addressable Market with SubQ Path
TG Therapeutics delivered a record Q1, exceeding revenue and patient milestones, while raising full-year guidance and accelerating its pipeline. The company’s base of BrionV patients surpassed 25,000 globally, with recurring demand and new patient growth both outpacing expectations. Subcutaneous and streamlined dosing programs position the franchise to nearly double its addressable market, with pivotal data and regulatory catalysts approaching.
Summary
- Installed BrionV Base Surges: Over 25,000 patients now treated, shifting the business to a recurring, predictable model.
- Pipeline Expansion Accelerates: Subcutaneous and simplified dosing programs set to unlock new market segments and operating leverage.
- Capital Allocation Balances Growth: Share repurchases and disciplined business development reflect confidence and selective risk-taking.
Business Overview
TG Therapeutics develops and commercializes therapies for autoimmune diseases, with its lead product BrionV (IV anti-CD20 therapy, relapsing multiple sclerosis) as the primary revenue driver. The company generates income through U.S. and ex-U.S. product sales, licensing, and royalties. Its business model centers on recurring treatment regimens, pipeline expansion into new indications, and lifecycle management via new formulations.
Performance Analysis
Q1 marked a pivotal inflection in scale and predictability for TG Therapeutics. U.S. net product revenue exceeded expectations, supported by a 63% YoY growth in BrionV, and the global patient base surpassed 25,000. This milestone transitions the business from early adoption to a recurring, cohort-driven model, where each new patient adds to a durable, expanding revenue stream. The commercial team cited record new patient starts and the highest-ever month in March, underscoring strong underlying demand and prescriber expansion.
Operating leverage is now materializing: Revenue growth outpaced OpEx, driving a near-quadrupling of operating income YoY. SG&A and R&D investments rose, reflecting both lifecycle programs (subcutaneous, enhanced dosing) and expanded DTC campaigns, but were offset by top-line strength. The balance sheet was fortified by an expanded Blue Owl facility, supporting both share repurchases and future BD flexibility.
- Recurring Revenue Engine: BrionV’s six-month dosing and strong persistence rates mean revenue builds cumulatively, not resetting annually.
- Outperformance Triggers Guidance Raise: Management increased U.S. and global revenue forecasts, reflecting confidence in underlying demand visibility.
- OpEx Growth Disciplined: Operating costs rose with pipeline and marketing expansion but remain controlled relative to revenue trajectory.
Momentum is now self-reinforcing, as higher patient persistence and new starts drive greater predictability, while the upcoming subcutaneous launch could unlock a step-change in scale.
Executive Commentary
"The first quarter of 2026 was, in my view, exceptional, not because of any single milestone, but because of the consistency and durability we're now seeing across the business... we continue to believe we are still early in the BrionV adoption curve, making peak revenue from the IV franchise alone still years ahead of us and multiples of where we are today."
Michael Weiss, Chairman and Chief Executive Officer
"At its core, this is a recurring treatment model. Patients who start BrionV are typically treated every six months, and we continue to see strong persistence over time, stronger than what we originally modeled. That means our revenue base doesn't reset each year. It builds."
Adam Waldman, Chief Commercial Officer
Strategic Positioning
1. Recurring Treatment Model Drives Predictability
The shift from early adoption to a recurring, installed base is transforming revenue visibility. BrionV’s six-month dosing and high persistence rates mean each new cohort adds to a compounding base, reducing volatility and enabling more accurate forecasting. This model is now reinforced by real-world data and DTC campaigns that are bringing more informed patients into the funnel.
2. Subcutaneous Launch to Double Addressable Market
The upcoming subcutaneous (SubQ) formulation is a strategic unlock. Currently, about 35% of the anti-CD20 market prefers or requires at-home self-administration, a segment TGTX does not serve today. The SubQ program—fully enrolled in Phase III and targeting 2028 launch—could nearly double BrionV’s market reach with minimal incremental cost, leveraging existing commercial infrastructure for significant operating leverage.
3. Enhanced Dosing Streamlines Onboarding
The “enhance” study targets operational simplicity by consolidating the initiation schedule. Moving from two infusions to one at start could reduce friction for patients and providers, further boosting adoption and lowering onboarding barriers. Top-line data is expected in the coming weeks, with a potential 2027 launch if successful.
4. Pipeline Expansion Beyond MS
BrionV is being positioned as a “pipeline within a product.” New studies are launching in myasthenia gravis and treatment-resistant schizophrenia, with Azercel (allogeneic CAR T) progressing in progressive MS. These efforts extend the franchise’s runway and diversify future growth sources.
5. Disciplined Capital Allocation and Share Repurchase
Management is actively repurchasing shares and pursuing selective business development. Over $100 million in buybacks this quarter signals confidence in intrinsic value, while the expanded Blue Owl facility preserves flexibility for opportunistic M&A.
Key Considerations
This quarter marks a step-function in BrionV’s market penetration and business model maturity, with strategic programs set to further expand the company’s reach and profitability. Investors should weigh the following:
- Installed Base Momentum: Over 25,000 patients treated globally, with record new starts and rising persistence, underpinning a recurring, compounding revenue base.
- SubQ Formulation as Growth Catalyst: Full Phase III enrollment and data expected by year-end, unlocking a new 35% market segment with minimal additional expense.
- Operational Simplicity as Competitive Edge: Enhanced dosing and streamlined onboarding reduce friction, supporting share gains against larger incumbents.
- Capital Deployment Discipline: Management preference for buybacks over high-priced BD reflects confidence in undervaluation and risk-adjusted returns.
- Pipeline Optionality: New indications and cell therapy programs provide long-term upside beyond core MS franchise.
Risks
Competitive intensity remains high, with established players launching new at-home and long-interval dosing options. Pipeline execution risk is nontrivial, especially in subcutaneous and new indications. Regulatory timelines, gross-to-net variability, and potential shifts in payer or physician preferences could impact growth. Capital allocation discipline will be tested if BD opportunities become more attractive relative to buybacks.
Forward Outlook
For Q2, TG Therapeutics guided to:
- Approximately $220 million in U.S. BrionV net revenue
For full-year 2026, management raised guidance:
- $885–900 million U.S. revenue
- Approximately $925 million total global revenue
- Operating costs of ~$350 million (excluding stock comp) plus ~$100 million for subcutaneous manufacturing
Management highlighted several factors that will drive results:
- Continued strength in new patient starts and persistence
- Upcoming data readouts for enhanced dosing and subcutaneous programs
Takeaways
- Durable Recurring Model: BrionV’s installed base and high persistence have transformed TGTX into a compounding, recurring revenue business with increasing predictability.
- Strategic Expansion: SubQ and enhanced dosing programs could nearly double the addressable market, amplifying scale without proportional cost increases.
- Pipeline and Capital Allocation: New indications and cell therapy development offer long-term optionality, while active buybacks and selective BD reflect management’s confidence and discipline.
Conclusion
TG Therapeutics is executing on both commercial and pipeline fronts, with a recurring revenue base, expanding addressable market, and disciplined capital deployment. The company’s trajectory is now defined by durable growth, operational leverage, and near-term catalysts that could reshape its competitive standing.
Industry Read-Through
TGTX’s performance and strategy signal a broader shift in the MS and autoimmune landscape. The move toward recurring, cohort-driven models with high persistence is setting a new standard for specialty pharma. The success of subcutaneous, at-home administration will pressure incumbents to accelerate their own lifecycle management and convenience-focused offerings. Share gains in both IV and SubQ segments will likely force competitors to invest more heavily in patient experience, DTC campaigns, and operational simplification. The company’s disciplined capital allocation, favoring buybacks over expensive M&A, could also influence peer strategies in an increasingly competitive capital environment.